AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR
Novel Imfinzi-based regimen significantly improved patient outcomes in resectable non-small cell lung cancer in AEGEAN Phase III trial. Strength of emerging proprietary antibody drug conjugates technology demonstrated with data across three assets. First clinical data for CAR-T cell therapy in solid tumours utilising AstraZeneca’s innovative research and armouring platform.AstraZeneca will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research (AACR) Annual Meeting, 14 to 19 April 2023. Data from 70